Quidelortho Corpoation ($QDEL) Stock Forecast: Down 6.1% Today

What is Quidelortho Corpoation?

QuidelOrtho (QDEL) specializes in diagnostic healthcare solutions, with a focus on respiratory testing products. Recently, the company's stock saw significant downward movement in the market.

Why is Quidelortho Corpoation going down?

QDEL stock is down 6.1% on Jun 5, 2026 14:17

• QuidelOrtho (QDEL) stock faced notable bearish trends, likely influenced by:
• Disappointing first-quarter 2026 financial results showing lower revenues and adjusted loss per share compared to the previous year.
• Decreased demand due to its high reliance on respiratory testing, impacting financial results.
• Analyst estimates pointing towards a negative trend, resulting in a Zacks Rank #5 (Strong Sell).
• The release of restricted stock units (RSUs) by company directors might have also played a role in the negative market sentiment towards the stock, suggesting internal concerns or uncertainty about the company's future performance.

QDEL Price Chart

QDEL Technical Analysis

QDEL News

QuidelOrtho (QDEL) Up 24.1% Since Last Earnings Report: Can It Continue?

Shares of QuidelOrtho (QDEL) have increased by 24.1% since its last earnings report, outperforming the S&P 500. Despite this, the company's first-quarter 2026 adjusted loss per share and revenues were below last year's figures, though revenue did surpass the Zacks Consensus Estimate. Analyst estimates for the stock have trended downward, leading to a Zacks Rank #5 (Strong Sell).

https://finance.yahoo.com/markets/stocks/articles/quidelortho-qdel-24-1-since-153025577.html

QuidelOrtho's Respiratory Exposure Remains a Key Near-Term Risk

QuidelOrtho (QDEL) faces significant near-term risk due to its high exposure to respiratory testing, as evidenced by a substantial decline in first-quarter 2026 revenue and adjusted loss per share attributed to a milder respiratory season. Despite stable market share, reduced demand severely impacted financial performance. The company's profitability and cash flow remain sensitive to respiratory demand fluctuations, differentiating it from more diversified peers like Abbott Laboratories and Thermo Fisher Scientific.

https://www.tradingview.com/news/zacks:b45791c3c094b:0-quidelortho-s-respiratory-exposure-remains-a-key-near-term-risk/

QuidelOrtho (QDEL) director RSUs vest into 6,829 shares, holding 19,469 directly

QuidelOrtho Corp director Mary Lake Polan, Ph.D., reported that 6,829 restricted stock units (RSUs) vested on May 29, 2026, converting into common stock at a $0.00 conversion price. Following this transaction, Polan directly holds 19,469 shares of QuidelOrtho common stock, with an additional 17,353 shares held indirectly through an LLC. This activity was detailed in a Form 4 SEC filing, indicating routine equity compensation.

https://www.stocktitan.net/sec-filings/QDEL/form-4-quidel-ortho-corp-insider-trading-activity-39cc865fd25f.html

QuidelOrtho (QDEL) director Ann D. Rhoads receives 6,829 shares as RSUs vest

QuidelOrtho (QDEL) director Ann D. Rhoads received 6,829 shares of common stock as restricted stock units (RSUs) vested on May 29, 2026. These RSUs were converted into common shares at no cost, which is a routine compensation event. Following this transaction, Rhoads directly holds 23,257 shares of QuidelOrtho common stock.

https://www.stocktitan.net/sec-filings/QDEL/form-4-quidel-ortho-corp-insider-trading-activity-f9690fe1feba.html

QuidelOrtho (QDEL) director adds 6,829 shares through RSU vesting

QuidelOrtho Corp director Kenneth F. Buechler received 6,829 shares of common stock on May 29, 2026, due to the vesting of restricted stock units (RSUs). These RSUs converted into shares at no exercise price, and Buechler now directly holds 108,750 shares of QuidelOrtho common stock. This transaction is classified as neutral in terms of impact and sentiment.

https://www.stocktitan.net/sec-filings/QDEL/form-4-quidel-ortho-corp-insider-trading-activity-51e5ed128b43.html

Trending Today

ZCash ($ZEC) Crypto Forecast: Up 10.2% Today

Stellar ($XLM) Crypto Forecast: Down 5.6% Today

Bitcoin ($BTC) Crypto Forecast: Up 5.1% Today

NASDAQ-100 ($NDX) Index Forecast: Down 5.2% Today

Ethereum ($ETH) Crypto Forecast: Up 5.3% Today

Quidelortho Corpoation Price History

15.04.2026 - QDEL Stock was down 5.6%

• The price target for QDEL dropped by 34.46% to $19.25, potentially influencing the bearish trend and reflecting doubts about the company's future performance.
• Despite a 3.0% increase in shares, trading below the GF Value™ of $37.22 suggests possible undervaluation. However, with a low Financial Strength score of 3/10, investors may be worried, leading to selling pressure.
• Positive perceptions of QDEL's stability and growth may have been overshadowed by concerns about missed free cash flow guidance and potential EBITDA impacts from Chinese policy changes, resulting in a cautious stance among traders and investors.
• The combination of a reduced price target, mixed valuation signals, and short-term financial challenges likely played a role in QDEL's recent bearish market movement.

03.05.2026 - QDEL Stock was up 5.0%

• QuidelOrtho's collaboration with Allo Hope Foundation to address HDFN in pregnancy indicates the company's commitment to enhancing healthcare outcomes and expanding its presence in critical areas.
• The director at QuidelOrtho receiving shares from RSU release demonstrates confidence in the company's future prospects, potentially contributing to the positive sentiment surrounding QDEL.
• The emphasis on education, early testing, and strategic partnerships align with current market preferences for companies that prioritize innovation and collaboration to tackle significant healthcare challenges.
• Overall, these positive developments likely fueled investor confidence and led to the uptrend in QDEL's stock price today.

03.05.2026 - QDEL Stock was up 10.7%

• QDEL's stock saw a bullish trend possibly due to the partnership announcement with the Allo Hope Foundation to boost education, connection, and early testing for alloimmunized pregnancies.
• The increase in shares acquired by various directors through RSU vesting might have boosted investor confidence and demonstrated faith in the company's growth trajectory.
• Collaborative efforts to improve prenatal care and address hemolytic disease of the fetus and newborn (HDFN) likely fueled investor enthusiasm about QDEL's potential advancements in the healthcare sector.

19.04.2026 - QDEL Stock was up 6.8%

• Despite a decrease in the price target by 34.46% to $19.25, QDEL experienced a strong bullish movement.
• The increase in short interest and cautious analyst sentiment may have initially contributed to bearish pressure on the stock.
• The miss on Q1 earnings estimates and declining revenues could have initially dampened investor confidence.
• The unexpected bullish movement in QDEL could be attributed to potential positive developments within the company, such as new product launches or strategic partnerships, leading investors to reassess the stock's value despite the negative news.

04.05.2026 - QDEL Stock was up 13.0%

• The positive sentiment surrounding QDEL's recent stock performance could be linked to company directors increasing their holdings through the vesting of restricted stock units (RSUs), signaling confidence in the company's future.
• Despite potential near-term risks related to its heavy reliance on respiratory testing, there appears to be optimism in the market regarding QDEL's ability to overcome challenges and seize future opportunities.
• The company's consistent market share, alongside regular compensation activities involving its directors, likely reassured investors about QDEL's growth potential, contributing to today's bullish market trend.

04.05.2026 - QDEL Stock was up 10.8%

• QuidelOrtho's stock surged by 24.1% since its last earnings report, despite reporting a decline in first-quarter 2026 revenue and adjusted loss per share. The revenue did surpass expectations, but analyst estimates have trended downward, resulting in a Zacks Rank #5 (Strong Sell).
• The company faces near-term risks due to its heavy reliance on respiratory testing, which was impacted by a milder respiratory season, leading to reduced demand and financial performance. This sensitivity to respiratory demand fluctuations sets it apart from more diversified competitors like Abbott Laboratories and Thermo Fisher Scientific.
• The positive sentiment from QuidelOrtho directors acquiring shares through RSU vesting may have contributed to the bullish movement, indicating confidence in the company's future prospects despite the challenges it currently faces.
• Overall, the market movement could be a result of a combination of better-than-expected revenue performance, director confidence through share acquisitions, and potential market optimism regarding the company's ability to navigate through its current challenges in the respiratory testing segment.

08.04.2026 - QDEL Stock was down 5.5%

• Citigroup and UBS have maintained a Neutral rating on QuidelOrtho and have adjusted their price targets downwards, indicating reduced confidence in the company's short-term performance.
• The considerable ownership stake held by Newtyn Management in QuidelOrtho may have intensified selling pressure on the stock as investors reassess their positions.
• QuidelOrtho's increased losses in Q1 2026, attributed to challenges in revenue growth and profitability forecasts, likely played a role in the prevailing negative sentiment toward the stock.
• Despite falling short of earnings expectations in Q1 2026, QuidelOrtho's strategic measures and optimistic outlook for the latter part of the year suggest potential for recovery, which may not be currently reflected in the market's movement.

05.05.2026 - QDEL Stock was down 6.1%

• QuidelOrtho (QDEL) stock faced notable bearish trends, likely influenced by:
• Disappointing first-quarter 2026 financial results showing lower revenues and adjusted loss per share compared to the previous year.
• Decreased demand due to its high reliance on respiratory testing, impacting financial results.
• Analyst estimates pointing towards a negative trend, resulting in a Zacks Rank #5 (Strong Sell).
• The release of restricted stock units (RSUs) by company directors might have also played a role in the negative market sentiment towards the stock, suggesting internal concerns or uncertainty about the company's future performance.

12.04.2026 - QDEL Stock was up 5.2%

• Despite recent downgrades from Jefferies and UBS, the overall sentiment in the market is positive towards QuidelOrtho, seen as a stable and growing business with significant mispricing.
• Investors focused on long-term customer contracts and potential growth catalysts like the new LEX product, eclipsing short-term headwinds.
• Actions by analysts like downgrades and price target adjustments initially caused uncertainty, but the market viewed these as temporary setbacks rather than long-term concerns, resulting in the bullish movement.
• The market sentiment suggests that QuidelOrtho's strong fundamentals and growth potential outweigh the short-term challenges highlighted by analysts.

06.04.2026 - QDEL Stock was down 8.3%

• QuidelOrtho Corporation (QDEL) faced a strong bearish movement attributed to its Q1 2026 financial results falling below expectations, impacting revenue and profitability.
• An 11% revenue decline was reported, mainly due to reduced demand for U.S. respiratory products and operational adjustments.
• Despite strategic initiatives such as the acquisition of Lex Diagnostics and cost-saving plans, uncertainties in the Chinese market and weaker performance in key regions added to the negative market sentiment.
• Concerns about pricing challenges in China and meeting revenue targets for 2026 might be leading to investor caution regarding QuidelOrtho’s performance, driving the bearish market movement.

28.04.2026 - QDEL Stock was up 6.6%

• QuidelOrtho Corp (QDEL) stock saw a bullish trend despite being deemed undervalued by GF Value™, signaling a positive outlook from investors.
• The recent launch of episode 58 of a podcast by QuidelOrtho Corporation, which focused on hemolytic disease of the fetus and newborn (HDFN), likely boosted awareness about the company's diagnostic capabilities and solutions, contributing to the optimistic market sentiment.
• Investor confidence may have been bolstered by the discussions on prompt diagnostics and coordinated care for HDFN, showcasing QuidelOrtho Corp's expertise and potential for enhanced results. This led to increased investor interest and the upward movement of the stock.

11.04.2026 - QDEL Stock was down 5.0%

• An analyst downgraded QuidelOrtho (QDEL) from Hold from Buy and lowered its price target, while another adjusted its price target to $12 from $17 but kept a Neutral rating, influencing the negative investor sentiment.
• Another analyst maintained a Neutral rating on QuidelOrtho, possibly contributing to the lack of positive movement in the stock.
• The disclosure of a significant ownership stake by Newtyn Management in QuidelOrtho might also have impacted investor sentiment, hinting at uncertainty among market participants.
• Taken together, the downgrades, price target adjustments, and ownership stake disclosure likely played a role in the bearish movement observed in QDEL today.